Psyence Biomedical Ltd. (PBM)
NCM · Healthcare · Biotechnology
Closing price as of 2026-07-29 · Source: TEK2day Finance
Key Metrics
About Psyence Biomedical Ltd.
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company has a strategic collaboration with PsyLabs to produce Ibogaine. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
Quarterly Financials
| Metric | 2024-09-30 | 2025-09-30 |
|---|---|---|
| Revenue | 0.00 | 0.00 |
| Operating Income | -1.2M | -1.5M |
| Net Income | 141K | -753K |
| Diluted EPS | $25.44 | $-3.19 |
Annual Financials
| Metric | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -3.2M | -44.2M | -3.7M | -6.2M |
| Net Income | -3.2M | -51.2M | 1.0M | -6.9M |
| Diluted EPS | $-940.02 | $-14,274.29 | $261.02 | $nan |